Houston-based Pharm-Olam said its presence in 40 countries combined with JSS’ post-marketing, health economics and outcome studies will attract sponsors seeking to carry out complex analysis of global clinical development programmes.
The strategy of combining trial capacity in emerging hubs like Russia and Latin America with specialist post-market analysis fits with both growing pharma industry demand for treatment naive trial populations and increasing regulatory pressure for more post-approval studies.